Intelligent Bio Solutions Inc. (INBS)
NASDAQ:INBS
Want to see INBS full AI Analyst Report?
INBS Stock Chart & Stats
$1.03
-$0.03(-2.02%)
At close: 4:00 PM EST
$1.03
-$0.03(-2.02%)
Day’s Range― - ―
52-Week Range$2.29 - $24.90
Previous CloseN/A
Volume32.28K
Average Volume (3M)83.92K
Market Cap
$5.00M
Enterprise Value$4.27M
Total Cash (Recent Filing)$740.37K
Total Debt (Recent Filing)$3.45M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.12
Shares Outstanding2,001,173
10 Day Avg. Volume60,111
30 Day Avg. Volume83,923
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)3.03
Price to Sales (P/S)2.97
P/FCF Ratio-0.92
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue1.19
Enterprise Value/Gross Profit3.99
Enterprise Value/Ebitda-0.42
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manufacturing Scale-up & Margin ImprovementThe Syrma Johari manufacturing partnership materially scales production fourfold, enabling faster fulfillment and inventory build-up ahead of U.S. rollout. Targeted >40% unit cost cuts and ~20ppt gross margin improvement are structural, improving long-term unit economics and competitive pricing flexibility.
Top-line Momentum And Healthy Gross MarginsImproving revenue alongside a sustained ~46% gross margin indicates the core product and consumables economics are solid. Recurring consumable sales tied to installed readers create predictable revenue streams and support scalable gross profitability as volumes and deployments increase.
Manageable Leverage And Strengthened Equity BaseLow leverage provides balance-sheet flexibility to fund near-term operational needs without heavy interest burden. A larger equity base improves liquidity headroom and enables the company to pursue scaling initiatives while preserving capacity for additional capital if commercialization requires investment.
Bears Say
High And Persistent Cash BurnSustained negative operating and free cash flow of roughly -$9.4M to -$9.7M TTM signals the business is not yet self-funding. This structural cash burn increases reliance on external financing, compresses runway, and elevates execution risk until scale and margin improvements generate positive cash flow.
Very Weak Profitability And Negative ReturnsExtreme negative net margins and poor return metrics reflect a cost base far exceeding current revenue. Even with improving gross margins, large operating losses indicate the company must materially scale revenue or cut costs to reach breakeven; otherwise losses will continue to erode shareholder value.
Ongoing Equity Issuance And Dilution RiskRepeated use of ATM offerings, warrant exercises and equity awards denotes reliance on equity to fund operations. While providing near-term capital, this structural financing approach increases share count over time, diluting existing holders and potentially reducing per-share upside absent definitive improvement in profitability.
Intelligent Bio Solutions News
INBS FAQ
What was Intelligent Bio Solutions Inc.’s price range in the past 12 months?
Intelligent Bio Solutions Inc. lowest stock price was $2.29 and its highest was $24.90 in the past 12 months.
What is Intelligent Bio Solutions Inc.’s market cap?
Intelligent Bio Solutions Inc.’s market cap is $5.00M.
When is Intelligent Bio Solutions Inc.’s upcoming earnings report date?
Intelligent Bio Solutions Inc.’s upcoming earnings report date is May 13, 2026 which is in 6 days.
How were Intelligent Bio Solutions Inc.’s earnings last quarter?
Intelligent Bio Solutions Inc. released its earnings results on Feb 12, 2026. The company reported -$2.82 earnings per share for the quarter, missing the consensus estimate of N/A by -$2.82.
Is Intelligent Bio Solutions Inc. overvalued?
According to Wall Street analysts Intelligent Bio Solutions Inc.’s price is currently Overvalued.
Does Intelligent Bio Solutions Inc. pay dividends?
Intelligent Bio Solutions Inc. does not currently pay dividends.
What is Intelligent Bio Solutions Inc.’s EPS estimate?
Intelligent Bio Solutions Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Intelligent Bio Solutions Inc. have?
Intelligent Bio Solutions Inc. has 2,001,173 shares outstanding.
What happened to Intelligent Bio Solutions Inc.’s price movement after its last earnings report?
Intelligent Bio Solutions Inc. reported an EPS of -$2.82 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.667%.
Which hedge fund is a major shareholder of Intelligent Bio Solutions Inc.?
Currently, no hedge funds are holding shares in INBS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Technical Analysis
Ownership Overview
4.52% Insiders
0.75% Mutual Funds
<0.01% Other Institutional Investors
94.43% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---